Literature DB >> 342665

The interaction in vitro of Pneumocystis carinii with macrophages and L-cells.

H Masur, T C Jones.   

Abstract

A model was developed for studying the interaction between Pneumocystis, rat-derived cells, and humoral factors. Pneumocystis were obtained in large quantity by bronchial lavage of steroid-treated rats. The trophozoite was the predominant form obtained, and it could readily be recognized by phase contrast microscopy. Organisms maintained a typical morphology for at least 3 days in culture, and 10-20% took up radiolabeled nucleotides. Pneumocystis readily adhered to cell surfaces in a similar manner in alveolar macrophages from steroid-treated or normal rats, mouse peritoneal macrophages, and L-cells. Adherent organisms were not interiorized to a significant degree in the absence of antipneumocystis serum. After addition of rabbit antipneumocystis serum, rapid interiorization of organisms occurred from the surface of macrophages but not L-cells. Organisms appeared to be promptly destroyed within macrophages after interiorization. Persisting or multiplying intracellular forms were not seen. Antipneumocystis serum did not morphologically alter Pneumocystis. These observations suggest a role for antibody and mononuclear phagocytes during the immune response to Pneumocystis.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 342665      PMCID: PMC2184105          DOI: 10.1084/jem.147.1.157

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  23 in total

1.  FACTORS INVOLVED IN THE ADHERENCE OF S. TYPHIMURIUM C5 AND MOUSE PERITONEAL MACROPHAGES.

Authors:  I AUZINS; D ROWLEY
Journal:  Aust J Exp Biol Med Sci       Date:  1963-10

2.  Pneumocystis carinii pneumonia in the United States. Epidemiologic, diagnostic, and clinical features.

Authors:  P D Walzer; D P Perl; D J Krogstad; P G Rawson; M G Schultz
Journal:  Ann Intern Med       Date:  1974-01       Impact factor: 25.391

3.  Immunohistochemistry in studies on the pathogenesis of Pneumocystis pneumonia in infants.

Authors:  W J Brzosko; K Madaliński; K Krawczyński; A Nowoslawski
Journal:  Ann N Y Acad Sci       Date:  1971-06-21       Impact factor: 5.691

4.  Propagation of Pneumocystis carinii in vitro.

Authors:  L L Pifer; W T Hughes; M J Murphy
Journal:  Pediatr Res       Date:  1977-04       Impact factor: 3.756

5.  Properties of antibodies cytophilic for macrophages.

Authors:  A Berken; B Benacerraf
Journal:  J Exp Med       Date:  1966-01-01       Impact factor: 14.307

Review 6.  Pneumocystis carinii as the cause of human disease: historical perspective and magnitude of the problem: introductory remarks.

Authors:  D C Gajdusek
Journal:  Natl Cancer Inst Monogr       Date:  1976-10

7.  Pneumocystis carinii in vitro: A study by scanning electron microscopy.

Authors:  M J Murphy; L L Pifer; W T Hughes
Journal:  Am J Pathol       Date:  1977-02       Impact factor: 4.307

8.  Red cells coated with immunoglobulin G: binding and sphering by mononuclear cells in man.

Authors:  A F LoBuglio; R S Cotran; J H Jandl
Journal:  Science       Date:  1967-12-22       Impact factor: 47.728

9.  Lung biopsy in Pneumocystis carinii pneumonia: a histopathologic study of typical and atypical features.

Authors:  W R Weber; F B Askin; L P Dehner
Journal:  Am J Clin Pathol       Date:  1977-01       Impact factor: 2.493

10.  The interaction in vitro of Mycoplasma pulmonis with mouse peritoneal macrophages and L-cells.

Authors:  T C Jones; J G Hirsch
Journal:  J Exp Med       Date:  1971-02-01       Impact factor: 14.307

View more
  59 in total

Review 1.  Immunological features of Pneumocystis carinii infection in humans.

Authors:  P D Walzer
Journal:  Clin Diagn Lab Immunol       Date:  1999-03

2.  Rapid microscopy technique for detection of Pneumocystis carinii in fresh clinical specimens.

Authors:  G Chichino; A Bruno; C Cevini; S Gatti; M Scaglia
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-08       Impact factor: 3.267

3.  Role of fibronectin in Pneumocystis carinii attachment to cultured lung cells.

Authors:  S T Pottratz; W J Martin
Journal:  J Clin Invest       Date:  1990-02       Impact factor: 14.808

4.  Pneumocystis jirovecii pneumonia in two patients with systemic lupus erythematosus after rituximab therapy.

Authors:  F Bonilla-Abadía; J F Betancurt; J C Pineda; J D Vélez; G J Tobón; C A Cañas
Journal:  Clin Rheumatol       Date:  2014-01-09       Impact factor: 2.980

5.  Cdc42 and RhoB activation are required for mannose receptor-mediated phagocytosis by human alveolar macrophages.

Authors:  Jianmin Zhang; Jinping Zhu; Xia Bu; Melanie Cushion; T Bernard Kinane; Hava Avraham; Henry Koziel
Journal:  Mol Biol Cell       Date:  2004-12-01       Impact factor: 4.138

6.  Pneumocystis pneumonia. Animal model: pneumocystis cartinii pneumonia in the immunosuppressed rat.

Authors:  F W Chandler; J K Frenkel; W G Campbell
Journal:  Am J Pathol       Date:  1979-05       Impact factor: 4.307

7.  Analyses of rat Pneumocystis carinii antigens recognized by human and rat antibodies by using western immunoblotting.

Authors:  D C Graves; S J McNabb; M A Worley; T D Downs; M H Ivey
Journal:  Infect Immun       Date:  1986-10       Impact factor: 3.441

8.  Human immunodeficiency virus type 1 infection of human macrophages modulates the cytokine response to Pneumocystis carinii.

Authors:  O Kandil; J A Fishman; H Koziel; P Pinkston; R M Rose; H G Remold
Journal:  Infect Immun       Date:  1994-02       Impact factor: 3.441

9.  Effect of transcription factor GATA-2 on phagocytic activity of alveolar macrophages from Pneumocystis carinii-infected hosts.

Authors:  Mark E Lasbury; Xing Tang; Pamela J Durant; Chao-Hung Lee
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

10.  Both immunity and hyperresponsiveness to Pneumocystis carinii result from transfer of CD4+ but not CD8+ T cells into severe combined immunodeficiency mice.

Authors:  J B Roths; C L Sidman
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.